LIBTAYO can be administered in a hospital, clinic or infusion center as a 30-minute intravenous (IV) infusion every three weeks until the disease progresses or if side effects become intolerable.

In a small study in a community oncology practice, more than 60% of patients with advanced squamous cell skin cancer treated ...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

THIO sequenced with Libtayo extended overall survival in those with non ... leads to profound and sustained tumor regression in advanced cancer models. This effect is attributed to the induction of ...

The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell ...